ClinicalTrials.gg
RecruitingNCT07191106APIMICIUpdated Sep 24, 2025

Pilot Study Assessing the Feasibility and Impact of a Remote Adapted Physical Activity Program on Quality of Life in Patients With Inflammatory Bowel Disease (IBD)

An interventional study of adapted physical activity in Inflammatory Bowel Disease (IBD) and Inflammatory Bowel Disease (Crohn&Amp;#39;s Disease and Ulcerative Colitis), sponsored by Raincy Montfermeil Hospital Group. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-24.

Primary conditionColitis, UlcerativeRegistry: Inflammatory Bowel DiseasesReclassifiedWhy we changed it
Registry
Inflammatory Bowel Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Colitis, Ulcerative
Why
  1. The study's listed conditions name Colitis, Ulcerative, a narrower term within Inflammatory Bowel Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Raincy Montfermeil Hospital Group · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year ago, but the record still lists the study as recruiting.
  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
72
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 239 studies in Colitis, Ulcerative with a site in France — 45 open to participants now, 78 under way, 27 of them phase 3. Colitis, Ulcerative · France.

Planned enrollment
148th of 184
72 · median 196
Started
2025
with 17 others
No phase
35 of 239
11 open now
Primary completion
2025-10
later than 10 of 77 live
Registered
221st of 239
by date

Among the 239 studies in Colitis, Ulcerative with a site in France, this one is the 148th largest by planned enrollment of the 184 interventional ones that give a count, is one of 18 that started in 2025, is one of 35 with no phase, reaches primary completion later than 10 of the 77 other live ones, and was the 221st registered.

Colitis, Ulcerative

1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

45 of the 239 studies in Colitis, Ulcerative with a site in France are open now. Recruiting first, the newest first:

39 more — sign in →

All 45 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 239 studies in Colitis, Ulcerative with a site in France, or all of them as a file.
02

Study summary

Inflammatory Bowel Disease (IBD) is a chronic relapsing condition that affects the gastrointestinal tract and is increasingly diagnosed in adolescents and young adults. Although anti-TNFα therapies are effective in reducing disease activity and improving quality of life, they are frequently associated with side effects such as fatigue, weight gain, and joint pain, which may be mitigated by regular physical activity.

Emerging evidence suggests that light to moderate physical activity may help reduce systemic and intestinal inflammation and improve IBD-related outcomes. However, access to structured physical activity programs remains limited, and personal or professional constraints may hinder participation.

This pilot study aims to assess the feasibility and impact of a remotely delivered Adapted Physical Activity (APA) program on the quality of life of patients with Inflammatory Bowel Disease (IBD), including Crohn's disease and ulcerative colitis. This study evaluates the effects of a 12-weeks remote APA intervention on quality of life as the primary outcome.

Secondary objectives include assessing changes in anxiety and depression, fatigue levels, IBD activity, and smoking behavior. The findings from this study may inform the development of scalable, non-pharmacological strategies to support symptom management and well-being in individuals with IBD.

03

Conditions studied

  • Inflammatory Bowel Disease (IBD)
  • Inflammatory Bowel Disease (Crohn&Amp;#39;s Disease and Ulcerative Colitis)

Browse trials for

Keywords

  • IBD, crohn, ulcerative colitis
04

In context

Colitis, Ulcerative Reclassified

1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.

This study's planned enrollment of 72 is close to the median of 70 across 1,239 interventional studies indexed under Colitis, Ulcerative.

Browse Colitis, Ulcerative studies →

Lead sponsor

Raincy Montfermeil Hospital Group is the lead sponsor of 8 studies on the registry; 1 is open to participants now.

Compared within Colitis, Ulcerative, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Inflammatory Bowel Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years and older
  • Diagnosis of Inflammatory Bowel Disease (IBD) established for at least 6 months
  • Patient is motivated to participate in the Adapted Physical Activity (APA) program
  • Medical certificate confirming fitness to engage in remote physical activity
  • Access to a digital device with internet connectivity enabling use of the MOOV+ application at home
  • Written freely given after appropriate information
  • Affiliation with, or beneficiary of, a national health insurance system

Exclusion criteria

Exclusion Criteria:

  • Patients under 18 years of age
  • Medical to physical activity
  • High levels of physical activity as defined by the International Physical Activity Questionnaire (IPAQ):

    • Total >1500 MET-min/week of vigorous activity on at least 3 days, OR
    • Total physical activity >3000 MET-min/week, regardless of distribution
  • Presence of psychological disorders that may interfere with study participation
  • Lack of access to a device or internet connection enabling remote participation
  • Pregnant or breastfeeding women
  • Patients under legal guardianship or curatorship
  • Patients under legal protection
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Pre- and post-intervention comparison following participation in the Adapted Physical Activity (APA)

    There is no comparator group at this stage of the research. Patient data will be compared before and after participation in the Adapted Physical Activity (APA) program.

    Procedure: adapted physical activity

Interventions

  • Procedureadapted physical activity

    Comparative before-and-after study over a 3-month period of remote Adapted Physical Activity (APA) delivered through the MOOV+ application

07

What researchers measure

Primary outcomes

  1. Impact of a Remote Adapted Physical Activity Program Delivered via the MOOV+ Application on Quality of Life in Patients With Inflammatory Bowel Disease: A Pilot Before-and-After Study

    Change in total Inflammatory Bowel Disease Questionnaire (IBDQ-32) score between baseline and the end of the program at Month 3 (M3)

    Time frame: From baseline (Month 0) to Month 3

Secondary outcomes

  1. evaluate the effect of the program on the different subdomains of health-related quality of life, including bowel symptoms, systemic symptoms, emotional function, and social function

    Variation in the four IBDQ-32 subscale scores between baseline (Month 0) and the end of the program (Month 3)

    Time frame: From baseline (Month 0) to Month 3

  2. Assess the feasibility of the Remote Adapted Physical Activity Program

    Variation of participation rate (number of enrolled patients / number of eligible patients)

    Time frame: From baseline (Month 0) to Month 3

  3. Assess the feasibility of the of the Remote Adapted Physical Activity Program

    Adherence to the program measured by session attendance rate (sessions attended / sessions scheduled) and dropout rate (number and reasons for early withdrawal).

    Time frame: From baseline (Month 0) to Month 3

  4. impact of APA on psychological status

    HADS score

    Time frame: From baseline (Month 0) to Month 3

  5. impact of APA on fatigue level

    FACIT fatigue score

    Time frame: From baseline (Month 0) to Month 3

  6. Impact of APA on IBD activity_ crohn's disease

    variation of Harvey-Bradshaw Index (HBI)

    Time frame: From baseline (Month 0) to Month 3

  7. Impact of APA on IBD activity_ ulcerative colitis

    variation of partial mayo score

    Time frame: From baseline (Month 0) to Month 3

  8. evaluation of Persistence of physical activity

    International Physical Activity Questionnaire (IPAQ )

    Time frame: From baseline (Month 0) to Month 3

  9. Change in Biological Markers of Disease Activity (CRP and Fecal Calprotectin)

    The impact of Adapted Physical Activity (APA) on biological disease activity will be assessed through changes in C-reactive protein (CRP) levels and fecal calprotectin concentrations

    Time frame: From baseline (Month 0) to Month 3

  10. Evaluation of satisfaction level assessed using a 5-point Likert scale.

    Evaluation of Satisfaction with a Remote Adapted Physical Activity Program Delivered via MOOV+ (from "1:Very dissatisfied" to "5 : very satisfied")

    Time frame: month 3

08

Study locations

1 of 2 sites recruiting
09

References and documents

Publications

  • Nahon S, Lahmek P, Saas C, Durance C, Olympie A, Lesgourgues B, Gendre JP. Socioeconomic and psychological factors associated with nonadherence to treatment in inflammatory bowel disease patients: results of the ISSEO survey. Inflamm Bowel Dis. 2011 Jun;17(6):1270-6. doi: 10.1002/ibd.21482. Epub 2010 Oct 25. PubMed 21560190 ↗
  • Sarter H, Cretin T, Savoye G, Fumery M, Leroyer A, Dauchet L, Paupard T, Coevoet H, Wils P, Richard N, Turck D, Ley D, Gower-Rousseau C; EPIMAD study Group. Incidence, prevalence and clinical presentation of inflammatory bowel diseases in Northern France: a 30-year population-based study. Lancet Reg Health Eur. 2024 Oct 18;47:101097. doi: 10.1016/j.lanepe.2024.101097. eCollection 2024 Dec. PubMed 39478988 ↗
  • Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017 Apr 29;389(10080):1756-1770. doi: 10.1016/S0140-6736(16)32126-2. Epub 2016 Dec 1. PubMed 27914657 ↗
  • Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn's disease. Lancet. 2017 Apr 29;389(10080):1741-1755. doi: 10.1016/S0140-6736(16)31711-1. Epub 2016 Dec 1. PubMed 27914655 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Oct 2025, 1 month after the start.

Of 228 non-industry interventional studies with no phase under Colitis, Ulcerative, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 56. This study's planned 1 month is below that.

Counting every sponsor, half of 239 studies reached it within 34 months; a quarter within 15 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2025
First posted
Sep 24, 2025
StartActual
Sep 15, 2025
Primary completionEst.
Oct 30, 2025
CompletionEst.
Mar 31, 2026
Last update
Sep 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07191106
Lead sponsor
Raincy Montfermeil Hospital Group
Responsible party
Sponsor
First posted
Sep 24, 2025
Start date
Sep 15, 2025
Primary completion
Oct 30, 2025 (estimated)
Completion
Mar 31, 2026 (estimated)
Last update
Sep 24, 2025

Study contacts

Stephane NAHON, Professor
Contact
stephane.nahon@ght-gpne.fr
+33141708000

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion